Research Study

HELIOS-A: A Phase 3 Global, Randomized, Open-label Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Principal Investigator 
Michelle M. Mezei

Overview

Disorders and Conditions 
Amyloidosis
ClinicalTrials.gov# 
NCT03759379
Status 
Recruiting
Study Start/End 
Sep 11, 2019 to Feb 28, 2021
Locations 
Diamond Health Care Centre
Name/Title 
Deborah Kraus, Research Nurse
Phone 
604-875-4111 ext.22950
Email Address 
deborah.kraus@vch.ca
Purpose of Study 

The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis).

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.